Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Celgene acquires Avila Therapeutics for $350mm up front, $575mm in earn-outs

Executive Summary

Celgene Corp. is paying $350mm up front for private drug discovery company Avila Therapeutics Inc., which could also receive a total of $575mm in earn-outs: $195mm tied to development and approval of Avila’s lead candidate AVL292, and $380mm for the clinical progress and approval of therapeutics arising from Avila’s Avilomics platform.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Includes Earnout
    • Intra-Biotech Deal
    • Acquisition of Private Biotech

Related Companies

Advertisement
UsernamePublicRestriction

Register